Skip to main content
Top
Published in: Familial Cancer 1/2012

01-03-2012 | Original Article

Implications for cancer genetics practice of pro-actively assessing family history in a General Practice cohort in North West London

Authors: Kelly Kohut, Lucia D’Mello, Elizabeth K. Bancroft, Sarah Thomas, Mary-Anne Young, Kathryn Myhill, Susan Shanley, Brian H. J. Briggs, Michelle Newman, Ifthikhar M. Saraf, Penny Cox, Sarah Scambler, Lyndon Wagman, Michael T. Wyndham, Rosalind A. Eeles, Michelle Ferris

Published in: Familial Cancer | Issue 1/2012

Login to get access

Abstract

At present cancer genetics referrals are reactive to individuals asking for a referral and providing a family history thereafter. A previous pilot study in a single General Practice (GP) catchment area in North London showed a 1.5-fold increase in breast cancer risk in the Ashkenazi Jewish population compared with the non-Ashkenazi mixed population. The breast cancer incidence was equal in the Ashkenazim in both pre- and postmenopausal groups. We wanted to investigate the effect of proactively seeking family history data from the entire female population of the practice to determine the effect on cancer genetics referral. Objectives To determine the need for cancer genetics intervention for women in a single GP catchment area. (1) to determine the incidence and strength of family history of cancer in women aged over 18 in the practice, (2) to offer cancer genetics advice and determine the uptake of counselling in those with a positive family history, (3) to identify potential BRCA1/BRCA2 gene mutation carriers who can be offered clinical follow up with appropriate translational research studies. Design Population-based cohort study of one General Practice female population. Participants Three hundred and eighty-three women over the age of 18 from one General Practice who responded to a questionnaire about family history of cancer. The whole female adult GP population was the target and the total number sampled was 3,820. Results 10% of patients completed the questionnaire (n = 383). A family history of cancer was present in 338 cases, 95 went on to have genetic counselling or had previously had counselling and 47 were genetically tested. We identified three carriers of an Ashkenazi Jewish founder mutation in BRCA1. Conclusions Response rate to a family history questionnaire such as that used in genetics centres was low (10%) and other approaches will be needed to proactively assess family history. Although the Ashkenazim are present in 39% of the GP catchment area, 62% of those who returned a family history questionnaire were from this ethnic group and of those returned, 44% warranted referral to a cancer genetics unit. In the non Ashkenazim, the questionnaire return rate was 38% and 18% of those warranted referral to cancer genetics.
Literature
1.
go back to reference Antoniou AC, Pharoah PDP, Narod S et al (2005) Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet 42:602–603PubMedCrossRef Antoniou AC, Pharoah PDP, Narod S et al (2005) Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet 42:602–603PubMedCrossRef
2.
go back to reference Antoniou AC, Cunningham AP, Peto J et al (2008) The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 98:1457–1466PubMedCrossRef Antoniou AC, Cunningham AP, Peto J et al (2008) The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 98:1457–1466PubMedCrossRef
3.
go back to reference The Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. JNCI 9115:1310–1316 The Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. JNCI 9115:1310–1316
4.
go back to reference Domchek SM, Friebel TM, Neuhausen SL et al (2006) Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 7(3):223–229PubMedCrossRef Domchek SM, Friebel TM, Neuhausen SL et al (2006) Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 7(3):223–229PubMedCrossRef
5.
go back to reference Ferris M, Easton D, Doherty R et al (2007) A population-based audit of ethnicity and breast cancer risk in one General Practice catchment area in North London, UK: implications for practice. Hered Cancer Clin Pract 5(3):157–160PubMedCrossRef Ferris M, Easton D, Doherty R et al (2007) A population-based audit of ethnicity and breast cancer risk in one General Practice catchment area in North London, UK: implications for practice. Hered Cancer Clin Pract 5(3):157–160PubMedCrossRef
6.
go back to reference Grann VR, Jacobson JS, Thomason D et al (2002) Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. J Clin Oncol 20:2520–2529PubMedCrossRef Grann VR, Jacobson JS, Thomason D et al (2002) Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. J Clin Oncol 20:2520–2529PubMedCrossRef
7.
go back to reference Hartge P, Struewing JP, Wacholder S et al (1999) The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Human Genet 64:963–970CrossRef Hartge P, Struewing JP, Wacholder S et al (1999) The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Human Genet 64:963–970CrossRef
8.
go back to reference Metcalfe KA, Poll A, Royer R et al (2010) Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol 28:387–391PubMedCrossRef Metcalfe KA, Poll A, Royer R et al (2010) Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol 28:387–391PubMedCrossRef
9.
go back to reference Rubenstein WS, Jiang H, Dellafave L et al (2009) Cost-effectiveness of population-based BRCA1/2 testing and ovarian cancer prevention for Ashkenazi Jews: a call for diaglogue. Genet Med 22:629–639CrossRef Rubenstein WS, Jiang H, Dellafave L et al (2009) Cost-effectiveness of population-based BRCA1/2 testing and ovarian cancer prevention for Ashkenazi Jews: a call for diaglogue. Genet Med 22:629–639CrossRef
10.
go back to reference Struewing JP, Hartge P, Wacholder S et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401–1408PubMedCrossRef Struewing JP, Hartge P, Wacholder S et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401–1408PubMedCrossRef
11.
go back to reference Thompson D, Easton DF (2001) Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Human Genet 68:410–419CrossRef Thompson D, Easton DF (2001) Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Human Genet 68:410–419CrossRef
12.
go back to reference Tonin P, Weber B, Offit K et al (1996) Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 2:1179–1183PubMedCrossRef Tonin P, Weber B, Offit K et al (1996) Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 2:1179–1183PubMedCrossRef
Metadata
Title
Implications for cancer genetics practice of pro-actively assessing family history in a General Practice cohort in North West London
Authors
Kelly Kohut
Lucia D’Mello
Elizabeth K. Bancroft
Sarah Thomas
Mary-Anne Young
Kathryn Myhill
Susan Shanley
Brian H. J. Briggs
Michelle Newman
Ifthikhar M. Saraf
Penny Cox
Sarah Scambler
Lyndon Wagman
Michael T. Wyndham
Rosalind A. Eeles
Michelle Ferris
Publication date
01-03-2012
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 1/2012
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-011-9482-6

Other articles of this Issue 1/2012

Familial Cancer 1/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine